- Home
- PLRX vs TCRX Comparison
PLRX vs TCRX Comparison
Compare PLRX & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLRX | TCRX |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.3M | 64.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PLRX | TCRX |
|---|---|---|
| Price | $1.16 | $0.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $3.75 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 896.1K | 457.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $286.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.09 | $0.88 |
| 52 Week High | $3.46 | $2.57 |
Technical Indicators
Market Signals| Indicator | PLRX | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.47 | 41.45 |
| Support Level | $1.09 | $0.91 |
| Resistance Level | $1.22 | $1.00 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 29.55 | 22.57 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.